UK Pioneering Technology used for Pre-Clinical Study to Deliver Enhanced Cell Re-Population

UK pioneering technology shown in Yale University study to regenerate dCELL® implant using the host’s own stem cells

Tissue Regenix has announced that a pre-clinical study, undertaken by Professor Alan Dardik from the Department of Surgery at Yale University, using Tissue Regenix Group Plc’s patented dCELL® technology, has been published in a peer-reviewed paper and has demonstrated that the Tissue Regenix dCELL® matrix can deliver enhanced cell re-population.

dCELL® is a process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.

The pre-clinical study examined the types of cells that repopulated Tissue Regenix’s proprietary dCELL® scaffold and compared these to a competitor, once both had been implanted. The study was performed using the Company’s vascular patch that is currently approved for use in the EU.

Findings highlighted that Tissue Regenix’ dCELL® Vascular Patch was effective at attracting the right stem cell types quickly for the function they will have in the final tissue structure. This, in conjunction with the Company’s own clinical observations, gives further support to the expectation that patients can get the benefit of stem cell repopulation without the significant issues and costs associated with using externally sourced stem cells.

Professor Alan Dardik commented: “We unexpectedly found that the dCELL® patches attracted arterial progenitor cells to their surface one week after implantation, whereas a competitor bovine patch did not show this at this time. These findings support the incorporation and healing of dCELL® patches into the body as well as their resistance to infection.”

Tissue Regenix is developing further applications of its dCELL® technology platform, for example, by progressing an dialysis graft for patients with kidney disease into the clinic, which, it is hoped, will mitigate some of the associated risks and reduce the cost of expensive dialysis.